These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 22430048)
1. Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumours. Pantaleo MA; Nannini M; Saponara M; Gnocchi C; Di Scioscio V; Lolli C; Catena F; Astolfi A; Di Battista M; Biasco G; Anticancer Drugs; 2012 Jun; 23(5):567-72. PubMed ID: 22430048 [TBL] [Abstract][Full Text] [Related]
2. [The importance of mutational status in prognosis and therapy of GIST]. Comandone A; Boglione A Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775 [TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Sawaki A; Nishida T; Doi T; Yamada Y; Komatsu Y; Kanda T; Kakeji Y; Onozawa Y; Yamasaki M; Ohtsu A Cancer; 2011 Oct; 117(20):4633-41. PubMed ID: 21456006 [TBL] [Abstract][Full Text] [Related]
4. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458 [TBL] [Abstract][Full Text] [Related]
5. The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use. Koh Y; Lee HE; Oh DY; Kim JH; Lee SH; Kim SH; Kim DW; Im SA; Kim TY; Heo DS; Kim WH; Bang YJ Jpn J Clin Oncol; 2012 Nov; 42(11):1020-7. PubMed ID: 22952296 [TBL] [Abstract][Full Text] [Related]
6. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192 [TBL] [Abstract][Full Text] [Related]
7. Efficacy evaluation of nilotinib treatment in different genomic subtypes of gastrointestinal stromal tumors: A meta-analysis and systematic review. Zhao Z; Zhang J; Zhang W; Tan S; Wei HT; You J; Guo S; Wang J; Chen P; Xu Y; Zong L Curr Probl Cancer; 2021 Jun; 45(3):100705. PubMed ID: 33495025 [TBL] [Abstract][Full Text] [Related]
8. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS). Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409 [TBL] [Abstract][Full Text] [Related]
9. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424 [TBL] [Abstract][Full Text] [Related]
10. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hornick JL; Fletcher CD Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861 [TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects. Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372 [TBL] [Abstract][Full Text] [Related]
12. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Heinrich MC; Corless CL; Demetri GD; Blanke CD; von Mehren M; Joensuu H; McGreevey LS; Chen CJ; Van den Abbeele AD; Druker BJ; Kiese B; Eisenberg B; Roberts PJ; Singer S; Fletcher CD; Silberman S; Dimitrijevic S; Fletcher JA J Clin Oncol; 2003 Dec; 21(23):4342-9. PubMed ID: 14645423 [TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Nishida T; Doi T; Naito Y Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162 [TBL] [Abstract][Full Text] [Related]
14. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. Heinrich MC; Rankin C; Blanke CD; Demetri GD; Borden EC; Ryan CW; von Mehren M; Blackstein ME; Priebat DA; Tap WD; Maki RG; Corless CL; Fletcher JA; Owzar K; Crowley JJ; Benjamin RS; Baker LH JAMA Oncol; 2017 Jul; 3(7):944-952. PubMed ID: 28196207 [TBL] [Abstract][Full Text] [Related]
15. Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503. Liu NN; Ohkouchi M; Hashikura Y; Kajimoto N; Matsuda I; Isozaki K; Toh Y; Takahashi T; Nishida T; Hirota S Lab Invest; 2013 May; 93(5):502-7. PubMed ID: 23459373 [TBL] [Abstract][Full Text] [Related]
16. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. Lee JH; Kim Y; Choi JW; Kim YS J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323 [TBL] [Abstract][Full Text] [Related]